Through its unique and integrated technology platform, Tengion is researching and developing product candidates with the potential to transform the treatment of organ and tissue impairment, failure and loss. The Company's plan is to develop, manufacture, and market a suite of autologous regenerative products.
The Company's portfolio currently consists of autologous regenerative product candidates in various stages of development, with a focus on the genitourinary and cardiovascular systems.
Tengion has brought together top scientists from throughout the world who are working diligently to develop neo-organs and tissues to meet urgent human needs. While our mission is vital, we must proceed with caution. Before we can make our product candidates available, they must be proven to be safe and effective, as judged by the rigorous standards of the U.S. Food and Drug Administration (FDA).
If you have medical questions, you should discuss them with your own doctor. We cannot provide any medical guidance.
The Company’s IND to study the Tengion Neo-Bladder in patients was accepted by the FDA in 2006, and we have initiated three Phase II clinical trials at multiple medical centers in the U.S.
More information on Phase II clinical trials is available at www.clinicaltrials.gov.